Improving pharmaceutical innovation by building a more comprehensive database on drug development and use

Health Affairs

Volumn 34, Issue 2, 2015, Pages 319-327

  Daniel, Gregory W ^a   Cazé, Alexis ^b   Romine, Morgan H ^c   Audibert, Céline ^b   Leff, Jonathan S ^b   McClellan, Mark B ^d  

^a Evidence development and innovation Engelberg Center for Health Care Reform at Brookings   (United States)

^b LP   (United States)

^c Engelberg Center for Health Care Reform at Brookings   (United States)

^d Health Care Innovation and Value Initiative Engelberg Center for Health Care Reform at Brookings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; CLINICAL RESEARCH; DATA BASE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH CARE POLICY; HUMAN; INFORMATION PROCESSING; PATIENT ADVOCACY; PRODUCT DEVELOPMENT; REIMBURSEMENT; UNITED STATES; COOPERATION; DRUG DATABASE; ECONOMICS; PHARMACEUTICS; PHARMACY RESEARCH; POSTMARKETING SURVEILLANCE; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; TRENDS;

COOPERATIVE BEHAVIOR; DATABASES, PHARMACEUTICAL; DRUG APPROVAL; DRUG INDUSTRY; EUROPEAN UNION; HUMANS; PHARMACY RESEARCH; PRODUCT SURVEILLANCE, POSTMARKETING; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES;

EID: 84922756124     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.1019     Document Type: Article

References (17)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151-85.
2. President's Council of Advisors on Science and Technology. Report to the president on propelling innovation in drug discovery, development, and evaluation [Internet]. Washington (DC): Executive Office of the President; 2012 Sep [cited 2014 Dec 19]. Available from: http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-fdafinal.pdf
3. Upton F. Curing disease with a little help from our friends. US News and World Report [serial on the Internet]. 2014 Mar 5 [cited 2014 Dec 19]. Available from: http://www.usnews.com/opinion/articles/2014/03/05/fda-drug-approval-must-keep-upwith-modern-technology
4. Berndt ER, Gottschalk AH, Philipson TJ, Strobeck MW. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nat Rev Drug Discov. 2005;4(7): 545-54.
5. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8(12):959-68.
6. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther. 2011;89(2):183-8.
7. Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov. 2010;9(11): 867-82.
8. Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med. 2011;343(6):535-41.
9. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191-200.
10. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51.
11. Roberts SA, Allen JD, Sigal EV. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. Health Aff (Millwood). 2011;30(7):1375-81.
12. Lanthier M, Miller KL, Nardinelli C, Woodcock J. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Health Aff (Millwood). 2013;32(8):1433-39.
13. Harrington M. From HIV to tuberculosis and back again: a tale of activism in 2 pandemics. Clin Infect Dis. 2010;50(Suppl 3):S260-6.
14. Ledford H. "Master protocol" aims to revamp cancer trials. Nature. 2013;498(7453):146-7.
15. Herbst R, Gandara D, Hirsch F, Redman M, LeBlanc M, Sparks D, et al. Lung-MAP-biomarker-driven master protocol for accelerating development of therapies for squamous cell lung cancer. Clin Cancer Res. (Forthcoming).
16. Citeline. About Citeline: a pharmaceutical clinical trials leader [Internet]. New York (NY): Citeline, c2015 [cited 2015 Jan 8]. Available from: http://www.citeline.com/about-us/
17. Infinata. BioPharm solutions suite [Internet]. Boston (MA): Infinata; c 2014 [cited 2015 Jan 8]. Available from: http://www.infinata.com/biopharma-solution.html